Acceleration Therapeutics' AT-101 Device Provides Beneficial Effect of Vasodilatation in Published Study.

NORTH BAY VILLAGE, Fla. -- Acceleration Therapeutics, a division of Non-Invasive Monitoring Systems, Inc. (OTCBB:NIMU) announced today that a published study using its AT-101 passive exercise device showed, for the first time, that the AT-101 produces an important benefit that also occurs with active exercise.

The President of Acceleration Therapeutics, Dr. Marvin Sackner, explained that, "One of the most important benefits of active exercise is to cause the release of nitric oxide into the bloodstream, a molecule that has direct vasodilator and anti-arteriosclerotic properties as well as indirect anti-inflammatory and anti-tumorigenic properties. The AT-101 increased vasodilatation through release of nitric oxide in all healthy subjects and patients who participated in this study."

The paper, entitled, "Nitric Oxide is Released into Circulation with Whole-Body, Periodic Acceleration," is published in the January 2005 issue of Chest, a peer-reviewed scientific journal. Dr. Sackner and associates from Mt. Sinai Medical Center, Miami Beach, Florida, conducted the study. Sackner is Emeritus Director of Medical Services at Mt. Sinai and Voluntary Professor of Medicine, University of Miami.

Dr. Sackner also noted that the results of this study suggest, "The AT-101 might substitute for or complement active exercise in those patients whose medical condition limits physical activity."

Passive exercise is the movement of the limbs or body of a person who does not or cannot exert voluntary control of their appropriate muscles. Passive exercise with the AT-101 produced one of the important benefits of active exercise for healthy and diseased individuals. This published study found that the AT-101 increased nitric oxide activity in 14 healthy persons and 40 patients, with diseases such as osteoarthritis of hips and knees, Parkinson's disease, multiple sclerosis, neuropathy, carpal tunnel syndrome, fibromyalgia, chronic fatigue syndrome, post-stroke spasticity, post-polio syndrome, and coronary artery disease.

The AT-101 is Acceleration Therapeutics' flagship product. This device is a non-invasive, powered exercise device, consisting of a comfortable horizontal platform/mattress that moves the body repetitively in a back and forth motion from head to foot.

Acceleration Therapeutics http://www.accelerationtherapeutics.com, is a leading developer of scientifically-advanced medical devices that offer effective non-invasive, drug-free treatments for people suffering from diseases, conditions and injuries that cause limited mobility or impaired circulation.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.